X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AlloNK (AB-101) is an allogeneic NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies or NK cell engagers. in combination with rituximab or obinutuzumab for the treatment of lupus nephritis.
Lead Product(s): AB-101,Rituximab,Cyclophosphamide
Therapeutic Area: Nephrology Product Name: AlloNK
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
AlloNK (AB-101) is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with Combination with Rituximab in Lupus Nephritis.
Lead Product(s): AB-101,Rituximab
Therapeutic Area: Immunology Product Name: AlloNK
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2023
Details:
AFM13 is a first-in-class innate cell engager (ICE®) that uniquely leverags the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages to destroy CD30-positive hematologic tumors.
Lead Product(s): AFM13,AB-101
Therapeutic Area: Oncology Product Name: AFM13
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Affimed
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
Under the terms of the agreement, Affimed and Artiva will pursue the development of the AFM13/AB-101 combination treatment in the United States on a co-exclusive basis. Affimed will lead regulatory activities through Phase 2 and any confirmatory studies.
Lead Product(s): AFM13,AB-101
Therapeutic Area: Oncology Product Name: AFM13
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Affimed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 03, 2022
Details:
AB-101, an ADCC enhancer NK-cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers. Artiva is currently advancing a Phase 1/2 of AB-101 in combination with rituximab for the treatment of relapsed or refractory B-cell lymphomas.
Lead Product(s): AB-101,Rituximab,Interleukin 2
Therapeutic Area: Oncology Product Name: AB-101
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
AB-201 is an allogeneic HER2-targeted CAR-NK cell therapy for the treatment of solid tumors in the outpatient setting with the option for repeat dosing. AB-201 has demonstrated potent anti-tumor activity in multiple preclinical HER2-positive tumor model systems.
Lead Product(s): CAR-NK Cell Therapy
Therapeutic Area: Oncology Product Name: AB-201
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Details:
Artiva’s pipeline includes AB-101, an ADCC enhancer NK-cell therapy which is currently under Phase 1/2 clinical trial in combination with rituximab for the treatment of relapsed or refractory B-cell lymphomas.
Lead Product(s): AB-101,Rituximab,Interleukin 2
Therapeutic Area: Oncology Product Name: AB-101
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Venrock Healthcare Capital
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 26, 2021
Details:
The collaboration initially includes two CAR-NK programs (AB-MK-001 and AB-MK-002) with an option for a third, none of which are in Artiva’s current or planned pipeline.
Lead Product(s): AB-MK-001
Therapeutic Area: Oncology Product Name: AB-MK-001
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $1,866.0 million Upfront Cash: $30.0 million
Deal Type: Collaboration January 28, 2021
Details:
The company plans to enter the clinic this year with AB-101 in combination with an anti-CD20 monoclonal antibody for the treatment of relapsed refractory B-cell lymphoma.
Lead Product(s): AB-101,Anti-CD20 monoclonal antibody
Therapeutic Area: Oncology Product Name: AB-101
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: 5AM Ventures
Deal Size: $78.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 26, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
